Table 4.
Baseline characteristics of patients <12 years.
| Patients, number (%) | 108 |
|---|---|
| Age, median (range) | 6 years (1–12) |
| • ≤6 years | • 52 (48) |
| • >6 years | • 56 (72) |
| Disease, number (%) | |
| • Malignant | 72 (67) |
| • Non-malignant | 36 (33) |
| Conditioning, number (%) | NA in 30 |
| • Myeloablative | 30 (38) |
| • Reduced intensity | 39 (50) |
| • Non myeloablative | 9 (12) |
| Donor, number (%) | NA in 30 |
| • Matched related donor | 12 (15) |
| • Matched unrelated donor | 50 (65) |
| • Mismatched ( ≤ 7/8) unrelated donor | 10 (12) |
| • Haploidentical donor | 6 (8) |
| Source, number (%) | NA in 36 |
| • BM | 49 (68) |
| • PBSC | 16 (22) |
| • CB | 7 (10) |
| Type of GvHD, number (%) | NA in 30 |
| Acute | 51 (65) |
| ○ III-IV | ○ 29 (57) |
| ○ Gut | ○ 39 (76) |
| Chronic | 27 (35) |
| ○ Severe | ○ 12 (44) |
| ○ Lung | ○ 12 (44) |
| Previous therapies, number (%) | NA in 30 |
| • median (range) | 3 (1–7) |
| • TNF inhibitors | 27 (35) |
| • CNI | 28 (36) |
| • ECP | 25 (32) |
| • Sirolimus | 24 (31) |
| • MSC | 18 (23) |
| • Other (basiliximab, ibrutinib, tocilizumab) | 25 (32) |
NA not available, BM bone marrow, PBSC peripheral blood stem cells, CB cord blood, TNF tumor necrosis factor, CNI calcineurin inhibitor, ECP extracorporeal photopheresis, MSC mesenchymal stromal cells.